DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)--$IMV #DeliveryPlatform--IMV Inc. (“IMV” or the “Company”) (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX®
Zanidatamab zovodotin (ZW49) accepted for oral presentation of Phase 1 clinical data at European Society for Medical Oncology (ESMO) Congress in September Announced Early Research and Development (eR&D) day presentation and webcast for October 20t
Signed worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (also known as RP-3500) Repare received a $125 million upfront payment in July 2022 as part of the collaboration agreement with Roch
SAN MATEO, Calif.--(BUSINESS WIRE)--#Clinicaltrials--Sagimet Biosciences, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, announced today that it will present additional Phase 2a data hi
Net revenue increased to $28.2 million for Q2 2022; Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS® (voclosporin) for 2022 Continued increases in LUPKYNIS Patients on Treatment; Steady Conversion Rates and Payor Covera
Nutrien is accelerating growth initiatives and announces intention to complete its existing 10 percent share repurchase program in 2022 All amounts are in US dollars except as otherwise noted SASKATOON, Saskatchewan--(BUSINESS WIRE)--Nutrien Ltd. (TSX a
Atlas' stealth-stage company will leverage AbCellera’s technology to start and advance new drug programs with enhanced speed and capital efficiency VANCOUVER, British Columbia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) and Atl
OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intak
Eat Well Group’s wholly-owned subsidiary, Belle Pulses Ltd. reports record revenue, gross profit, and net earnings amid greater global emphasis on food security while CPG investees continue to accelerate production in order to meet demand VANCOUVER, Br
TORONTO--(BUSINESS WIRE)--Organic Potash Corporation (CNSX: OPC) (“OPC” or the “Corporation”) announced today that the Corporation is extending the private placement offering that was previously announced on July 6, 2022 (placement of up to One Hu
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.